BR0313588A - Métodos para o tratamento da demência com base em apo e genótipo - Google Patents

Métodos para o tratamento da demência com base em apo e genótipo

Info

Publication number
BR0313588A
BR0313588A BR0313588-8A BR0313588A BR0313588A BR 0313588 A BR0313588 A BR 0313588A BR 0313588 A BR0313588 A BR 0313588A BR 0313588 A BR0313588 A BR 0313588A
Authority
BR
Brazil
Prior art keywords
methods
apo
genotype
treatment
dementia
Prior art date
Application number
BR0313588-8A
Other languages
English (en)
Inventor
Roger Michael Lane
Mihael Hristos Polymeropoulos
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0313588A publication Critical patent/BR0313588A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)

Abstract

"MéTODOS PARA O TRATAMENTO DA DEMêNCIA COM BASE EM APO E GENóTIPO". A presente invenção refere-se a métodos para prevenir o agravamento e/ou melhorar o funcionamento cognitivo ou problemas de comportamento em pacientes com demência por meios de genotipagem de ApoE para orientar o uso de drogas AChEI, incluindo rivastigmina. Da mesma forma incluídos, estão os kits para determinar a condição de ApoE4 e estratégia de tratamento recomendada.
BR0313588-8A 2002-08-07 2003-08-06 Métodos para o tratamento da demência com base em apo e genótipo BR0313588A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40169402P 2002-08-07 2002-08-07
PCT/EP2003/008719 WO2004015140A1 (en) 2002-08-07 2003-08-06 Methods for the treatment of dementia based on apo e genotype

Publications (1)

Publication Number Publication Date
BR0313588A true BR0313588A (pt) 2005-07-12

Family

ID=31715721

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313588-8A BR0313588A (pt) 2002-08-07 2003-08-06 Métodos para o tratamento da demência com base em apo e genótipo

Country Status (14)

Country Link
US (3) US20060160079A1 (pt)
EP (1) EP1529116B1 (pt)
JP (1) JP2005534710A (pt)
CN (1) CN1681941A (pt)
AT (1) ATE435302T1 (pt)
AU (1) AU2003266967B2 (pt)
BR (1) BR0313588A (pt)
CA (1) CA2494585A1 (pt)
DE (1) DE60328198D1 (pt)
DK (1) DK1529116T3 (pt)
ES (1) ES2327914T3 (pt)
IL (1) IL166466A0 (pt)
PT (1) PT1529116E (pt)
WO (1) WO2004015140A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
EP1784509A2 (en) * 2004-07-20 2007-05-16 Wyeth a Corporation of the State of Delaware Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer's disease
US20060228728A1 (en) * 2005-01-31 2006-10-12 Perlegen Sciences, Inc. Genetic basis of Alzheimer's disease and diagnosis and treatment thereof
US7740593B2 (en) 2005-12-09 2010-06-22 Senorx, Inc Guide block for biopsy or surgical devices
PT2650380E (pt) 2007-07-31 2016-01-14 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2729622C (en) 2008-07-03 2017-07-25 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
US11957115B2 (en) 2017-03-21 2024-04-16 The Jackson Laboratory Genetically modified mouse expressing human APOE4 and mouse Trem2 p.R47H and methods of use thereof
SG11201909895UA (en) 2017-05-24 2019-11-28 H Lundbeck As Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
EP3809838A4 (en) * 2018-06-21 2022-03-23 The Jackson Laboratory GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER'S DISEASE
US20220127680A1 (en) * 2019-02-28 2022-04-28 The Rockefeller Universtiy Apoe genotyping in cancer prognostics and treatment
JP2023509845A (ja) 2019-12-13 2023-03-10 インスピルナ，インコーポレーテッド 金属塩及びその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2148116T1 (es) * 1992-10-13 2000-10-16 Univ Duke Metodos de detectar la enfermedad de alzheimer.
CA2111503A1 (en) * 1993-12-15 1995-06-16 Mcgill University Apolipoprotein e polymorphism and alzheimer's disease
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
JP2000069963A (ja) * 1998-08-31 2000-03-07 Igaku Seibutsugaku Kenkyusho:Kk アポリポプロテインｅ４特異モノクローナル抗体
DE69923200T2 (de) * 1998-10-01 2005-12-22 Novartis Ag Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
ATE302751T1 (de) * 2000-06-30 2005-09-15 Elan Pharm Inc Verbindungen zur behandlung der alzheimerischen krankheit

Also Published As

Publication number Publication date
DE60328198D1 (de) 2009-08-13
AU2003266967A1 (en) 2004-02-25
WO2004015140A1 (en) 2004-02-19
EP1529116B1 (en) 2009-07-01
US20060160079A1 (en) 2006-07-20
ATE435302T1 (de) 2009-07-15
US20100240744A1 (en) 2010-09-23
CN1681941A (zh) 2005-10-12
ES2327914T3 (es) 2009-11-05
PT1529116E (pt) 2009-09-10
CA2494585A1 (en) 2004-02-19
EP1529116A1 (en) 2005-05-11
IL166466A0 (en) 2006-01-15
AU2003266967B2 (en) 2006-11-16
JP2005534710A (ja) 2005-11-17
US20080214662A1 (en) 2008-09-04
DK1529116T3 (da) 2009-11-09

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
IL166466A0 (en) Methods for the treatment of dementia based on apoe genotype
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
BRPI0606112A2 (pt) 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
CY1109551T1 (el) Πρωτεασωμικοι αναστολεις και μεθοδοι χρησιμοποιησης αυτων
SG147442A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
GB0802753D0 (en) Perylenequinone derivatives and uses thereof
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE409188T1 (de) Naphthyridinverbindungen
NO20081292L (no) Pentasykliske kinaseinhibitorer
GB0416508D0 (en) Therapeutic agents
SE0301650D0 (sv) Novel compounds
DK1408976T3 (da) Behandling af ADHD (Attention deficit hyperactivity disorder)
NO20053903D0 (no) Nukleotidlipidesterderivater.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]